Courtesy of the SBHCI. Intrepid is a 43-, 46-, and 50-mm nitinol self-expanding valve with bovine pericardial leaflets that is placed using a transapical delivery system with a 35-Fr access. This pilot study enrolled 50 patients with severe mitral regurgitation who were symptomatic and at a high surgical risk, or in whom surgery was contraindicated. Read<a href="https://solaci.org/en/2017/11/03/tct-2017-intrepid-mitral-replacement-with-a-self-expanding-device/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Avoiding general anesthesia in intervention procedures has the benefits of faster recovery and shorter hospitalization. This has been already analyzed in the context of TAVR, but not in MitraClip procedures. The present study analyzed 232 patients receiving the MitraClip. 76 of these procedures were done under general anesthesia (32.7%) and<a href="https://solaci.org/en/2017/10/27/mitraclip-procedure-can-be-performed-without-general-anesthesia/" title="Read more" >...</a>
Transcatheter aortic valve replacement (TAVR) was developed as a strategy to treat non-surgical aortic stenosis, and was later expanded to elderly patients at intermediate risk, because of increased operator experience (overcoming the learning curve) and improved devices. The present study presents the one year outcomes of the SOURCE 3 trial, the multicenter European registry of the<a href="https://solaci.org/en/2017/10/27/the-source-3-confirms-the-good-outcomes-of-the-sapien-3-at-one-year-followup/" title="Read more" >...</a>
The ADVANCE study was designed to evaluate the safety and effectiveness of transcatheter aortic valve replacement (TAVR) with self-expanding prosthesis CoreValve in “real world” patients with symptomatic, severe aortic stenosis at high surgical risk. Patients were enrolled from 44 experimental centers in 12 countries; treatment approach and choice of anaesthesia were determined by the local Heart Team.<a href="https://solaci.org/en/2017/10/25/new-study-confirms-tavr-durability-at-5-years/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. The presence of renal dysfunction in the “real world” is over 25% in patients who undergo transcatheter aortic valve implantation (TAVI). The evolution of this disease among patients who are subjected to a replacement is well known, but evidence for patients who undergo TAVI is still limited, particularly for those who<a href="https://solaci.org/en/2017/10/20/an-important-study-shows-that-renal-function-must-be-cared-for-in-tavr/" title="Read more" >...</a>
A recent presentation at London Valves took a closer look at the REPRISE III trial as regards two points that generated much discussion, such as need for a pacemaker and paravalvular leak. REPRISE III had previously demonstrated that the Lotus is noninferior to first-generation CoreValve and Evolut R in terms of safety. Additionally, it proved to be superior<a href="https://solaci.org/en/2017/10/18/reprise-iii-need-for-pacemaker-and-paravalvular-leak-with-lotus/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. The incidence of unprotected left main severe stenosis ranges between 4 and 8%, and it’s mostly associated with multivessel disease. The use of left ventricular support devices in high risk unprotected left main PCI is on the rise, but not much information available in this regard. Read also: “Prior assistance<a href="https://solaci.org/en/2017/10/18/impella-improves-safety-in-high-risk-unprotected-left-main-pci/" title="Read more" >...</a>
Paravalvular leak is complication derived from incomplete sealing between the implanted prosthesis and the native annulus, which occurs in 5% of all patients who undergo mitral valve replacement and 10% of those who undergo transcatheter aortic valve replacement. This is the most frequent non-structural valve dysfunction. While mild leaks can be asymptomatic, moderate to severe<a href="https://solaci.org/en/2017/10/12/transcatheter-reduction-or-surgery-for-paravalvular-leak-repair/" title="Read more" >...</a>
Transcatheter aortic valve replacement (TAVR) is often associated with conduction abnormalities, which usually end with permanent pacemaker (PPM) implantation in 10-40% of patients. Factors predisposing to PPM after TAVR have been studied in great detail, but their short- and long-term clinical impact is still controversial. Recently, outcomes from a large cohort of patients were<a href="https://solaci.org/en/2017/10/10/end-of-discussion-on-the-impact-of-pacemaker-after-tavr/" title="Read more" >...</a>
Cerebral ischemic events after transcatheter aortic valve replacement (TAVR) have been identified as independent predictors of morbidity and mortality. New-generation devices have managed to partially reduce the rate of cerebral events, but it still is around 5.5% at 30 days for patients undergoing TAVR through transfemoral access. First data on cerebral protection devices had only shown<a href="https://solaci.org/en/2017/09/29/it-is-a-fact-cerebral-protection-in-tavr-has-proved-to-reduce-stroke-and-death/" title="Read more" >...</a>